Developer docs
API playgroundTry for free, no card

Search company profiles

BTNX

Full company profile

uuid00088xa

Namestring
BTNX
Legal namestring
BTNX Inc.
Websiteurl
btnx.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

BTNX Inc. is a privately held Canadian biotechnology company founded in 1998 and headquartered in Pickering, Ontario. The company specializes in the research, development, and manufacture of rapid in-vitro diagnostic (IVD) tests and point-of-care diagnostics using lateral flow immunoassay technology, distributing products globally under the Rapid Response™ brand. BTNX also operates as a certified Original Equipment Manufacturer (OEM) of rapid diagnostic tests for third-party brands.

The company's product portfolio spans nine major diagnostic categories with 50+ SKUs: harm reduction test strips (fentanyl, xylazine, medetomidine, nitazene, benzodiazepine); infectious disease tests (HIV, Hepatitis A/B/C, COVID-19, influenza, strep A, RSV, and 30+ other pathogens); cancer screening via fecal immunochemical tests; cardiac markers (D-Dimer, CRP, troponin); fertility testing; urinalysis; glucose monitoring; wearable ECG patches (S-Patch); and drug/alcohol screening. Complementary software products include HL7/POCT1-A2 compliant data management systems, the RapidReader App, and the DASH Rapid PCR System. Products carry accuracy ratings of 98-99.9% with results typically available in 5-15 minutes.

BTNX generates revenue through direct product sales (B2B to healthcare facilities and B2C via e-commerce at btnx.com), OEM contract manufacturing, and multi-tier distributor networks spanning dozens of countries. Pricing follows a unit-pricing model with kit sizes from 5 to 100 tests (e.g., $15 CAD for fentanyl 10-pack; $100 CAD for 100-pack). The company holds ISO 13485:2016 certification, FDA clearances, Health Canada authorizations, and CE Marking, and is led by CEO and founder Iqbal Sunderani.

Short descriptiontext

BTNX Inc. is a Canadian biotechnology company that develops and manufactures rapid point-of-care in-vitro diagnostic tests under the Rapid Response brand, serving healthcare facilities, government health agencies, harm reduction programs, and consumers across more than 35 disease categories globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPickering, Canada
HQ citystring
Pickering
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid diagnostic tests, in-vitro diagnostics, point-of-care testing, lateral flow immunoassay, harm reduction test strips
Industry1 code
PRIMARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In-Vitro Diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Rapid Diagnostic Test Products
TypeOne Time License
Description

BTNX generates revenue through the sale of rapid point-of-care diagnostic test kits across multiple categories including infectious diseases, drug screening, fertility testing, urinalysis, glucose monitoring, cardiac markers, tumor markers, and harm reduction products. Products are sold in various formats (cassettes, strips, kits) to healthcare facilities and consumers.

btnx.com
2OEM Manufacturing
TypeHardware Sales
Description

BTNX operates as a certified Original Equipment Manufacturer (OEM) of rapid diagnostic tests, manufacturing products for other brands and companies under contract.

btnx.com
3Distribution and Resale
TypeOne Time License
Description

Revenue generated through a network of distributors who resell BTNX products to end customers globally, with the company focusing on providing high-quality products at competitive pricing to increase distributor margins.

btnx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details4 tiers
1COVID-19 Antigen Rapid Test Device - At Home (5 Pack)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$16.99 CAD per kit containing 5 tests, with expiration date of Oct 15, 2026. Authorized for home use under Health Canada Interim Order.

btnx.com
2Fentanyl Test Strips 10-pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$15.00 CAD for 10 test strips. Sensitivity: 200 ng/mL for liquid/powder samples.

btnx.com
3Fentanyl Test Strips 100-pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$100.00 CAD for 100 test strips with microscoops. For forensic and IVD use.

btnx.com
4Xylazine Test Strips 100-pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$275.00 CAD for 100 tests. Sensitivity: 1000 ng/mL. Can be used to test cocaine samples with no cross-reactivity with lidocaine.

btnx.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Rapid Response
Description

The primary brand under which BTNX distributes its diagnostic products including rapid test kits for drugs, infectious diseases, fertility, and other applications.

btnx.com
Core offering1 text field

BTNX researches, develops, and manufactures advanced in-vitro diagnostic (IVD) rapid test kits and point-of-care diagnostic devices sold under the 'Rapid Response' brand. Its catalog spans harm-reduction drug-checking strips, infectious disease panels, urinalysis, fertility, cardiac markers, glucose monitoring, tumor markers, and wearable ECG monitoring products, with both professional-use and at-home self-test SKUs. The company also operates as an OEM contract manufacturer and runs a consumer-direct e-commerce channel (btnx.com) in Canada and a U.S. distribution partnership with Lochness Medical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • HIV 1/2 Test Cassette: 99.9% accuracy, 10 minutes to result
+5 more records
Product overview1 text field

BTNX is a biotechnology company and world leader in rapid, point-of-care diagnostics. The company distributes its products under the Rapid Response™ brand and operates as a certified OEM of rapid diagnostic tests. BTNX offers a comprehensive portfolio of diagnostic products organized into major categories: (1) Harm Reduction products including Fentanyl, Xylazine (2.0), Medetomidine, Nitazene, and Benzodiazepine test strips for street drug checking; (2) Infectious Diseases tests covering HIV (3 formats including 4th generation), Hepatitis A/B/C, COVID-19 (home and professional), Influenza A&B, Strep A, RSV, and over 35 other pathogens; (3) Cancer Screening via Fecal Immunochemical Test (FIT) for colorectal cancer; (4) Glucose Monitoring including blood glucose meters and HbA1c analyzers; (5) Cardiac Markers for D-Dimer, CRP, and cardiac proteins; (6) Fertility Testing for pregnancy, ovulation, male fertility, and menopause; (7) Urinalysis products including reagent strips, analyzers, and UTI tests; (8) Wearable Monitoring Devices including S-Patch ECG patches; and (9) Drug Screening, Alcohol Testing, and Spiked Drink Detection products. The company also develops IT systems for point-of-care diagnostic data management using HL7/POCT1-A2 compliant software. Products are manufactured in ISO 13485:2016 certified facilities with global regulatory approvals including FDA, CE Mark, and Health Canada authorization.

Product and service1 record
1Fentanyl Test Strips (FYL)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeOthers
Description

Intertek is BTNX's ISO auditing company, conducting annual audits to certify BTNX's quality management system under ISO 13485:2016 standards.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Lochness Medical serves as BTNX's partner for US customers, directing US buyers to purchase BTNX products including fentanyl test strips, xylazine test strips, and other harm reduction products through their platform.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

BTNX is a premier supplier to Premier's healthcare alliance network, which brings together healthcare facilities and suppliers meeting rigorous standards for quality products.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Vancouver Coastal Health Authority offers Rapid Response Fentanyl Strips at their overdose prevention and supervised consumption sites and in their take-home drug testing kits in British Columbia.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

City of Hamilton's Drug Checking Program includes Rapid Response Fentanyl Test Strips and Xylazine Test Strips as part of their harm reduction services.

6Canadian Aboriginal and Minority Supplier Council (CAMSC)
Strategic tierMinorTypeOthers
Description

BTNX is a certified member of CAMSC as a business majority owned, managed, and controlled by visible minorities.

btnx.com
7Ajax-Pickering Board of Trade
Strategic tierMinorTypeOthers
Description

BTNX is a member of the Ajax-Pickering Board of Trade, the local business chamber in Pickering, Ontario.

btnx.com
Strategic tierCoreTypeTechnology or Integration
Description

BTNX builds strategic alliances with the most advanced innovative manufacturing facilities to accomplish efficient product development and sourcing infrastructure.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BTNX

In-Vitro Diagnosticsbtnx.com

BTNX Inc. is a Canadian biotechnology company that develops and manufactures rapid point-of-care in-vitro diagnostic tests under the Rapid Response brand, serving healthcare facilities, government health agencies, harm reduction programs, and consumers across more than 35 disease categories globally.

What BTNX does

BTNX Inc. is a privately held Canadian biotechnology company founded in 1998 and headquartered in Pickering, Ontario. The company specializes in the research, development, and manufacture of rapid in-vitro diagnostic (IVD) tests and point-of-care diagnostics using lateral flow immunoassay technology, distributing products globally under the Rapid Response™ brand. BTNX also operates as a certified Original Equipment Manufacturer (OEM) of rapid diagnostic tests for third-party brands.

The company's product portfolio spans nine major diagnostic categories with 50+ SKUs: harm reduction test strips (fentanyl, xylazine, medetomidine, nitazene, benzodiazepine); infectious disease tests (HIV, Hepatitis A/B/C, COVID-19, influenza, strep A, RSV, and 30+ other pathogens); cancer screening via fecal immunochemical tests; cardiac markers (D-Dimer, CRP, troponin); fertility testing; urinalysis; glucose monitoring; wearable ECG patches (S-Patch); and drug/alcohol screening. Complementary software products include HL7/POCT1-A2 compliant data management systems, the RapidReader App, and the DASH Rapid PCR System. Products carry accuracy ratings of 98-99.9% with results typically available in 5-15 minutes.

BTNX generates revenue through direct product sales (B2B to healthcare facilities and B2C via e-commerce at btnx.com), OEM contract manufacturing, and multi-tier distributor networks spanning dozens of countries. Pricing follows a unit-pricing model with kit sizes from 5 to 100 tests (e.g., $15 CAD for fentanyl 10-pack; $100 CAD for 100-pack). The company holds ISO 13485:2016 certification, FDA clearances, Health Canada authorizations, and CE Marking, and is led by CEO and founder Iqbal Sunderani.

BTNX firmographics

Firmographics
Name
BTNX
Legal name
BTNX Inc.
Website
https://btnx.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
BTNX Inc. is a Canadian biotechnology company that develops and manufactures rapid point-of-care in-vitro diagnostic tests under the Rapid Response brand, serving healthcare facilities, government health agencies, harm reduction programs, and consumers across more than 35 disease categories globally.
Ownership category
akta.pro rank

BTNX industry classification

Industry
Product category
In-Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Rapid diagnostic tests
  • In-vitro diagnostics
  • Point-of-care testing
  • Lateral flow immunoassay
  • Harm reduction test strips

Where BTNX is headquartered

Location

Headquarters

HQ city
Pickering
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

BTNX business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Rapid Diagnostic Test Products: BTNX generates revenue through the sale of rapid point-of-care diagnostic test kits across multiple categories including infectious diseases, drug screening, fertility testing, urinalysis, glucose monitoring, cardiac markers, tumor markers, and harm reduction products. Products are sold in various formats (cassettes, strips, kits) to healthcare facilities and consumers.
  2. OEM Manufacturing: BTNX operates as a certified Original Equipment Manufacturer (OEM) of rapid diagnostic tests, manufacturing products for other brands and companies under contract.
  3. Distribution and Resale: Revenue generated through a network of distributors who resell BTNX products to end customers globally, with the company focusing on providing high-quality products at competitive pricing to increase distributor margins.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCOVID-19 Antigen Rapid Test Device - At Home (5 Pack)
Unit PricingPay-as-you-goFentanyl Test Strips 10-pack
Unit PricingPay-as-you-goFentanyl Test Strips 100-pack
Unit PricingPay-as-you-goXylazine Test Strips 100-pack

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

BTNX product offering

Product offering

Core offering

BTNX researches, develops, and manufactures advanced in-vitro diagnostic (IVD) rapid test kits and point-of-care diagnostic devices sold under the 'Rapid Response' brand. Its catalog spans harm-reduction drug-checking strips, infectious disease panels, urinalysis, fertility, cardiac markers, glucose monitoring, tumor markers, and wearable ECG monitoring products, with both professional-use and at-home self-test SKUs. The company also operates as an OEM contract manufacturer and runs a consumer-direct e-commerce channel (btnx.com) in Canada and a U.S. distribution partnership with Lochness Medical.

Product overview

BTNX is a biotechnology company and world leader in rapid, point-of-care diagnostics. The company distributes its products under the Rapid Response™ brand and operates as a certified OEM of rapid diagnostic tests. BTNX offers a comprehensive portfolio of diagnostic products organized into major categories: (1) Harm Reduction products including Fentanyl, Xylazine (2.0), Medetomidine, Nitazene, and Benzodiazepine test strips for street drug checking; (2) Infectious Diseases tests covering HIV (3 formats including 4th generation), Hepatitis A/B/C, COVID-19 (home and professional), Influenza A&B, Strep A, RSV, and over 35 other pathogens; (3) Cancer Screening via Fecal Immunochemical Test (FIT) for colorectal cancer; (4) Glucose Monitoring including blood glucose meters and HbA1c analyzers; (5) Cardiac Markers for D-Dimer, CRP, and cardiac proteins; (6) Fertility Testing for pregnancy, ovulation, male fertility, and menopause; (7) Urinalysis products including reagent strips, analyzers, and UTI tests; (8) Wearable Monitoring Devices including S-Patch ECG patches; and (9) Drug Screening, Alcohol Testing, and Spiked Drink Detection products. The company also develops IT systems for point-of-care diagnostic data management using HL7/POCT1-A2 compliant software. Products are manufactured in ISO 13485:2016 certified facilities with global regulatory approvals including FDA, CE Mark, and Health Canada authorization.

Differentiator

Problem solved

Functional benefit

Brands

  • Rapid Response: The primary brand under which BTNX distributes its diagnostic products including rapid test kits for drugs, infectious diseases, fertility, and other applications.

Products and services

  • Fentanyl Test Strips (FYL)

Quantifiable outcome

  • HIV 1/2 Test Cassette: 99.9% accuracy, 10 minutes to result
  • +5 more outcomes

Companies that use BTNX

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

BTNX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BTNX partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, major and minor.

  • IntertekcoreOthersIntertek is BTNX's ISO auditing company, conducting annual audits to certify BTNX's quality management system under ISO 13485:2016 standards.
  • Lochness MedicalmajorChannel Partner/ Reseller/ DistributorLochness Medical serves as BTNX's partner for US customers, directing US buyers to purchase BTNX products including fentanyl test strips, xylazine test strips, and other harm reduction products through their platform.
  • Premier Health AlliancemajorChannel Partner/ Reseller/ DistributorBTNX is a premier supplier to Premier's healthcare alliance network, which brings together healthcare facilities and suppliers meeting rigorous standards for quality products.
  • Vancouver Coastal Health AuthoritymajorChannel Partner/ Reseller/ DistributorVancouver Coastal Health Authority offers Rapid Response Fentanyl Strips at their overdose prevention and supervised consumption sites and in their take-home drug testing kits in British Columbia.
  • City of HamiltonmajorChannel Partner/ Reseller/ DistributorCity of Hamilton's Drug Checking Program includes Rapid Response Fentanyl Test Strips and Xylazine Test Strips as part of their harm reduction services.
  • Canadian Aboriginal and Minority Supplier Council (CAMSC)minorOthersBTNX is a certified member of CAMSC as a business majority owned, managed, and controlled by visible minorities.
  • Ajax-Pickering Board of TrademinorOthersBTNX is a member of the Ajax-Pickering Board of Trade, the local business chamber in Pickering, Ontario.
  • Advanced Manufacturing PartnerscoreTechnology or IntegrationBTNX builds strategic alliances with the most advanced innovative manufacturing facilities to accomplish efficient product development and sourcing infrastructure.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

BTNX competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

BTNX compliance and trust

Trust signal

Compliance8 records

BTNX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BTNX leadership team

Management profile

Number of profiles

Profiles1 record

BTNX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BTNX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BTNX

What does BTNX do?

BTNX researches, develops, and manufactures advanced in-vitro diagnostic (IVD) rapid test kits and point-of-care diagnostic devices sold under the 'Rapid Response' brand. Its catalog spans harm-reduction drug-checking strips, infectious disease panels, urinalysis, fertility, cardiac markers, glucose monitoring, tumor markers, and wearable ECG monitoring products, with both professional-use and at-home self-test SKUs. The company also operates as an OEM contract manufacturer and runs a consumer-direct e-commerce channel (btnx.com) in Canada and a U.S. distribution partnership with Lochness Medical.

Is BTNX a public or private company?

BTNX is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BTNX founded?

BTNX was founded in 1996. It employs 11 to 50 people.

Where is BTNX based?

BTNX is headquartered in Pickering, Canada, in the North America region.

How does BTNX make money?

Three revenue lines are on record. Rapid Diagnostic Test Products are the primary driver. The others are OEM Manufacturing and distribution and Resale.

Does BTNX have an API?

No public API is recorded for BTNX.

What industry is BTNX in?

BTNX's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAIADAO, Home Diagnostic & Self-Test OTC Kits. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
360QuadrantsPoint of Care Diagnostics Startups/SMEs Companies Assessment, 2025A 2025 market assessment evaluates 11 startups and SMEs in the point-of-care diagnostics sector, categorizing them as progressive, responsive, or dynamic players based on product footprint and business excellence. The report highlights key companies including Boditech Med, ACON Laboratories, Trinity Biotech, EKF Diagnostics, and BTNX Inc., analyzing their strategic partnerships, technological innovations, and market positioning. It provides a comprehensive overview of market drivers such as decentralized healthcare demand and regulatory landscapes alongside competitive benchmarking data.PR NewswireHome Diagnostics Market Size, Share & Growth Statistics By Top Key Players - Abbott Laboratories, BTNX, Inc., Becton Dickinson & Company, ACON Laboratories, Inc | Brandessence Market ResearchBrandessence Market Research released a report forecasting significant revenue growth for the Global Home Diagnostics Market between 2022 and 2029, driven by chronic disease prevalence and demand for point-of-care testing. The study identifies key competitive players including Abbott Laboratories, Becton Dickinson & Company, and Roche Holding AG, while noting that North America currently dominates the market volume.PR NewswireU.S. Self-Testing Market to Surpass US$ 11.24 billion by 2028, Says Brandessence Market Research (BMRC)Brandessence Market Research published a report on the U.S. self-testing market, valued at US$ 12.6 billion in 2021 and projected to reach US$ 11.24 billion by 2028, reflecting a negative CAGR of -3.0%. Growth drivers include rising chronic disease prevalence, technological advancements, and increased e-commerce distribution, while concerns about unreliable results act as a restraint. The competitive landscape features Abbott Laboratories, Acon Laboratories Inc., Btnx Inc., Bionime Corporation, Roche Holding AG, Quidel Corporation, True Diagnostics Inc., Thermo Fisher Scientific, and Arkaray Inc.